Special Issues
Table of Content

Advances and Innovations in Head and Neck Cancer: Cutting-Edge Treatments and Future Directions

Submission Deadline: 31 May 2026 View: 618 Submit to Special Issue

Guest Editors

Assist. Prof. Domen Vozel

Email: domen.vozel@kclj.si

Affiliation: Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Ljubljana, SI-1000, Slovenia

Homepage:

Research Interests: head and neck cancers, skull-base pathology, rhinology, autologous regenerative treatment modalities, disease related quality of life


Prof. Primož Strojan

Email: pstrojan@onko-i.si

Affiliation: Department of Radiation Oncology, Institute of Oncology Ljubljana, SI-1000, Ljubljana, Slovenia.

Homepage:

Research Interests: head and neck cancers, melanoma and non-melanoma skin cancers, and the organizational aspects of radiotherapy


Summary

This special issue offers a comprehensive and in-depth exploration of the most recent advancements and emerging treatment strategies in the field of head and neck cancer. It features detailed discussions on innovative treatment modalities that improve tumor treatment precision while minimizing functional and cosmetic impacts on patients. Additionally, the issue highlights progress in targeted therapies, which aim to specifically attack cancer cells based on their genetic and molecular profiles, resulting in more effective and less toxic treatments. Immunotherapy, an exciting area of research, is also extensively covered, showcasing how harnessing the body's immune system can lead to durable responses and potential cures for advanced cancers. Advances in radiation therapy, including more precise delivery methods such as proton therapy, are examined for their role in reducing side effects and improving outcomes. Furthermore, the issue emphasizes personalized medicine approaches, where treatments are tailored to individual patient characteristics, genetic makeup, and tumor biology. This multidisciplinary effort involves collaborations among surgeons, oncologists, radiologists, and researchers, fostering innovation. The issue also discusses ongoing and future clinical trials that hold promise for redefining standard care protocols. Overall, this compilation aims to provide a thorough understanding of current challenges, recent breakthroughs, and future directions, ultimately shaping a more effective and patient-centered approach to managing head and neck cancers.


Keywords

head and neck cancer, emerging treatments, targeted therapy, immunotherapy, personalized medicine, clinical trials, multidisciplinary approach, cancer management.

Published Papers


  • Open Access

    REVIEW

    Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities

    Alessandro Polizzi, Gaetano Isola, Monia Cecati, Nicoletta Bonci, Roberto Campagna, Giovanni Tossetta
    Oncology Research, DOI:10.32604/or.2026.079642
    (This article belongs to the Special Issue: Advances and Innovations in Head and Neck Cancer: Cutting-Edge Treatments and Future Directions)
    Abstract Polyphenolic stilbenes are plant-derived compounds that have attracted increasing interest for their potential anticancer properties. Among them, resveratrol is the most extensively investigated molecule. Oral squamous cell carcinoma (OSCC) represents a major global health challenge due to its aggressive biological behavior, frequent late diagnosis, and limited improvement in survival outcomes despite advances in treatment. This review aims to summarize current experimental evidence on the anticancer effects of resveratrol in OSCC, also considering structurally related derivatives such as polydatin and pinostilbene hydrate. A structured review of the literature was performed to identify experimental studies investigating the… More >

  • Open Access

    CASE REPORT

    A Rare Collision Medullary and Papillary Thyroid Carcinoma in Autoimmune Thyroid Disease: Case Report

    Tena Šimunjak, Bernardica Jurić, Andro Košec, Vladimir Bedeković
    Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.072100
    (This article belongs to the Special Issue: Advances and Innovations in Head and Neck Cancer: Cutting-Edge Treatments and Future Directions)
    Abstract Background: Collision medullary and papillary thyroid carcinoma (MTC/PTC) is a rare entity, constituting less than 1% of all thyroid malignancies. The concurrent presence of these malignancies in patients with autoimmune thyroid disease, such as Graves’ disease, is even more uncommon. Calcitonin (Ctn) is considered one of the key MTC biomarkers. Mixed tumors may alter this relationship. Case Description: We report the case of a 55-year-old female with a history of Graves’ disease, who underwent total thyroidectomy for persistent dysthyroid orbitopathy. Histopathological analysis revealed a 9-mm collision MTC/PTC tumor in the left thyroid lobe, confirmed through More >

Share Link